Sensus (SRTS) Q1 2026 Earnings Transcript

Sensus Healthcare reported Q1 revenue of $3.4 million, down from $8.3 million, as sales to its historically largest customer disappeared; excluding that customer, revenue rose to $2.7 million, showing underlying diversification. Gross margin fell to 29.2% from 52.2% and adjusted EBITDA worsened to a $4.2 million loss, but management cited new CPT reimbursement codes, stronger pipeline activity, and the live SensusLink launch as catalysts for improving results later in 2026. The company ended the quarter with $18.3 million in cash, no debt, and 965 systems installed globally, and reiterated expectations for sequential revenue improvement and full-year profitability.

Analysis

The core story is not the headline revenue miss; it is a reset of the earnings mix. SRTS is moving from a single-customer, upfront-sale model to a slower-burn annuity model, which creates an air pocket in reported revenue and margin before it creates stability. That transition usually screens poorly in the near term because the market prices the visible denominator decline first, while underappreciating the optionality that comes from deferred revenue stacking once utilization normalizes.

The most important second-order effect is that the new reimbursement regime changes the buyer’s internal approval process, not just the economics. When coding risk drops to near-zero, the bottleneck shifts from physician enthusiasm to practice-level capex committee behavior, which favors financing, rentals, and shared-service structures. That should help customer conversion breadth, but it also mechanically suppresses near-term ASPs and reported gross margin because the revenue gets recognized over time instead of at shipment.

The contrarian setup is that the market may still be too focused on the old revenue concentration overhang and not enough on the removal of the reimbursement overhang. If the codes truly become “black-and-white,” then sales cycles should shorten after the initial proof-of-payment lag, with Q2/Q3 likely inflecting before the full benefit shows up in income statement optics. The key risk is that management’s guidance on profitability assumes adoption continues without a new concentration shock; if the prior major customer never returns, the business can still work, but the burden shifts to SensusLink/FDA utilization to close the gap faster than operating leverage burns cash.

For CMS-adjacent beneficiaries, the indirect read-through is modest but real: clearer reimbursement tends to accelerate procedure adoption in small specialty practices, which can lift utilization of adjacent billing and workflow systems. The bigger signal is competitive: if SRTS succeeds with a dedicated coding stack, peers in niche device categories will push harder for similar reimbursement clarity, which could create a multi-quarter lobbying and compliance tailwind across small-cap medtech.

Key Decisions for Investors

• Long SRTS on pullbacks over the next 1-3 weeks, targeting a Q2/Q3 inflection trade: upside comes from multiple expansion if revenue prints start to re-accelerate; risk is another quarter of ugly headline growth before deferred revenue becomes visible.
• Use a call spread rather than outright equity in SRTS (3-6 month tenor): prefer a defined-risk expression because the stock can stay depressed until the market sees conversion of pipeline into recognized revenue.
• Pair trade: long SRTS / short a higher-quality medtech name with limited reimbursement sensitivity over 1-2 quarters, to isolate the valuation rerating from reimbursement de-risking; exit if margin compression worsens or if utilization fails to offset mix drag.
• If already long, hedge with a near-dated put spread into the next earnings window: the main downside catalyst is not demand collapse but continued optics deterioration from FDA placements and mix, which can keep estimates under pressure.
• Watch for a confirming catalyst in 30-60 days: rising share of purchase transactions plus sequential improvement in gross margin. If both appear, add aggressively; if not, treat the story as a longer-duration transition, not an immediate earnings compounding trade.